ARRB2
Beta-arrestin-2
Also known as: ARR2, ARRB2_HUMAN, BARR2, DKFZp686L0365
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P32121
- Gene
- ARRB2
- Ensembl
- ENSG00000141480
- Chromosome
- 17
- Canonical length
- 409 aa
- Protein class
- Predicted intracellular proteins, Transporters
- Subcellular location
- Nucleoplasm,Plasma membrane,Cytosol
- Quaternary structure
- Homooligomer
OverviewNCBI Gene
Members of arrestin/beta-arrestin protein family are thought to participate in agonist-mediated desensitization of G-protein-coupled receptors and cause specific dampening of cellular responses to stimuli such as hormones, neurotransmitters, or sensory signals. Arrestin beta 2, like arrestin beta 1, was shown to inhibit beta-adrenergic receptor function in vitro. It is expressed at high levels in the central nervous system and may play a role in the regulation of synaptic receptors. Besides the brain, a cDNA for arrestin beta 2 was isolated from thyroid gland, and thus it may also be involved in hormone-specific desensitization of TSH receptors. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2012]
Canonical amino-acid sequenceUniProt
409 residues, UniProt reviewed canonical sequence.
>P32121|ARRB2
1 MGEKPGTRVF KKSSPNCKLT VYLGKRDFVD HLDKVDPVDG VVLVDPDYLK DRKVFVTLTC
61 AFRYGREDLD VLGLSFRKDL FIATYQAFPP VPNPPRPPTR LQDRLLRKLG QHAHPFFFTI
121 PQNLPCSVTL QPGPEDTGKA CGVDFEIRAF CAKSLEEKSH KRNSVRLVIR KVQFAPEKPG
181 PQPSAETTRH FLMSDRSLHL EASLDKELYY HGEPLNVNVH VTNNSTKTVK KIKVSVRQYA
241 DICLFSTAQY KCPVAQLEQD DQVSPSSTFC KVYTITPLLS DNREKRGLAL DGKLKHEDTN
301 LASSTIVKEG ANKEVLGILV SYRVKVKLVV SRGGDVSVEL PFVLMHPKPH DHIPLPRPQS
361 AAPETDVPVD TNLIEFDTNY ATDDDIVFED FARLRLKGMK DDDYDDQLCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ARRB2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 249 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 249 nTPM
- spleen: 158 nTPM
- appendix: 104 nTPM
- lung: 89 nTPM
- cerebellum: 64 nTPM
- hippocampal formation: 63 nTPM
Single-cell type
- neutrophils: 934 nCPM
- hofbauer cells: 396 nCPM
- monocytes: 334 nCPM
- kupffer cells: 251 nCPM
- neutrophil progenitors: 241 nCPM
- macrophages: 199 nCPM
Immune cell
- eosinophil: 270 nTPM
- neutrophil: 252 nTPM
- non-classical monocyte: 169 nTPM
- intermediate monocyte: 151 nTPM
- classical monocyte: 146 nTPM
- basophil: 117 nTPM
Brain region
- hypothalamus: 86 nTPM
- white matter: 86 nTPM
- hippocampal formation: 79 nTPM
- medulla oblongata: 75 nTPM
- cerebral cortex: 73 nTPM
- pons: 71 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.44
- gnomAD pLI
- 0.51
- gnomAD missense Z
- 2.38
- DepMap mean gene effect
- 0
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adult walking behavior
- beta-arrestin-dependent dopamine receptor signaling pathway
- cell chemotaxis
- desensitization of G protein-coupled receptor signaling pathway
- excitatory postsynaptic potential
- G protein-coupled receptor internalization
- modulation of chemical synaptic transmission
- negative regulation of canonical NF-kappaB signal transduction
- negative regulation of interleukin-1 beta production
- negative regulation of interleukin-12 production
- negative regulation of interleukin-6 production
- negative regulation of natural killer cell mediated cytotoxicity
- negative regulation of NF-kappaB transcription factor activity
- negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- negative regulation of protein ubiquitination
- negative regulation of toll-like receptor signaling pathway
- negative regulation of tumor necrosis factor production
- positive regulation of cardiac muscle cell differentiation
- positive regulation of cardiac muscle hypertrophy
- positive regulation of ERK1 and ERK2 cascade
- positive regulation of gene expression
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- positive regulation of receptor internalization
- positive regulation of synaptic transmission, dopaminergic
- proteasome-mediated ubiquitin-dependent protein catabolic process
- protein transport
- protein ubiquitination
- receptor internalization
- sensory perception of pain
- transcription by RNA polymerase II
- transforming growth factor beta receptor signaling pathway
- postsynaptic signal transduction
Molecular functions
- angiotensin receptor binding
- D1 dopamine receptor binding
- enzyme binding
- G protein-coupled receptor binding
- molecular adaptor activity
- protein kinase B binding
- protein-macromolecule adaptor activity
- signaling receptor binding
- ubiquitin protein ligase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ARRB2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ARRB2 as an antibody target. Whether an autoantibody or antibody against ARRB2 could matter depends on whether native ARRB2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ARRB2 is annotated at the cell surface, where native ARRB2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ARRB2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...